SCHEMBL3879523

SCHEMBL3879523

Cc1ccccc1NC(=O)N1CCC(c2nc3c(s2)CCN(C2CCC2)CC3)CC1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
FAAH O00519 2/20 0.48
GAA P10253 1/20 0.46
SMO Q99835 1/20 0.45
CCR3 P51677 1/20 0.45
KMT2A Q03164 1/20 0.41
LMNA P02545 3/20 0.41
TSHR P16473 1/20 0.41
MAPK1 P28482 1/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
TDP1 Q9NUW8 1/20 0.41
NPSR1 Q6W5P4 2/20 0.40
MAPT P10636 2/20 0.40
HTT P42858 2/20 0.40
PI4KB Q9UBF8 1/20 0.40
PKM P14618 1/20 0.39
ITGB3 P05106 1/20 0.39
ITGB1 P05556 1/20 0.39
ITGAV P06756 1/20 0.39
ITGA5 P08648 1/20 0.39
ITGA4 P13612 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3878937 0.85 MAPT (0.45) FAAHKMT2ALMNATSHRSMN1; SMN2
SCHEMBL3880220 0.84 HSD11B1 (0.46) KMT2ALMNAMAPK1HTTTP53
SCHEMBL3879524 0.84 FAAH (0.45) FAAHGAASMOCCR3KMT2A
SCHEMBL3880257 0.84 NPSR1 (0.49) FAAHKMT2ALMNANPSR1MAPT
SCHEMBL3878666 0.82 ACACB (0.35)
SCHEMBL3878786 0.81 ALDH1A1 (0.37) KMT2ALMNASMN1; SMN2PKMTP53
SCHEMBL3879027 0.80 PDE5A (0.42) KMT2ALMNASMN1; SMN2MAPT
SCHEMBL3879360 0.78 UBE2M (0.55) KMT2ALMNAMAPTTP53
SCHEMBL3884853 0.78 L3MBTL3 (0.34) LMNATSHRMAPK1NPSR1HTT
SCHEMBL3877921 0.78 GRM5 (0.46) GAAKMT2ALMNAMAPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP claimed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US claimed
EP-1858900-B1 FUSED THIAZOLE DERIVATIVES HAVING AFFINITY FOR THE HISTAMINE H3 RECEPTOR GLAXO GROUP LTD (GB) 2009-01-07 EP disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor GLAXO GROUP LIMITED 2008-07-03 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080161289-A1 Fused Thiazole Derivatives Having Affinity for the Histamine H3 Receptor HRH3, HRH4, HRH2 FAAH 249/4885GAA 1817/4885SMO 768/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.